The Outcomes and Complications in Patients Taking Warfarin under the Development of Holistic Care and Multidisciplinary-Team Approach in Nakhonpathom Hospital

Authors

  • Rawiwan Thongsongsang, M.D. Division of Medicine, Nakhonpathom Hospital

Keywords:

International normalized ratio (INR), time in therapeutic Range (TTR), warfarin, thromboembolism, bleeding

Abstract

Objective:  To evaluate the results of development of holistic care and multidisciplinary-approach in patients of the warfarin clinic, Nakhonpathom Hospital, and to compare the outcomes and complications before and after the development.

Methods:  A retrospective study was done in patients taking warfarin in warfarin clinic, Nakhonpathom Hospital before and after the project of development of holistic care in warfarin clinic by multidisciplinary team, during 1 February 2016 - 31 December 2017 for before the project and 1 January 2018-1 October 2018 for after the project. Outcomes, i.e., time in treatment range (TTR) and rates of complications of before and after the project were evaluated and compared.

Results:  Before the project development of holistic care in warfarin clinic by multidisciplinary team, 370 patients were included, 155 males (41.9%), 215 females (58.1%). Mean age was 64.3 years old (20-96). There were 203 atrial fibrillation (54.9%), 67 mitral stenosis with AF (18.1%), 30 post mechanical valve replacement (8.1%), 2 post bioprosthetic valve replacement (0.5%), 31 deep vein thrombosis (8.4%), 19 pulmonary embolism (5.1%), 4 stroke (1.1%), 1 arterial occlusion (0.3%), 1 intracardiac thrombus (0.3%) and 12 others (3.2%). After the project, 457 patients were included, 210 males (46.0%), 247 females (54.0%). Mean age was 64.0 years old (16-96). Of these, indications for warfarin were 247 atrial fibrillation (54.0%), 80 mitral stenosis with AF (17.5%), 42 post mechanical valve replacement (9.2%), 4 post bioprosthetic valve replacement (0.9%), 35 deep vein thrombosis (7.7%), 25 pulmonary embolism (5.5%), 7 stroke (1.5%), 1 arterial occlusion (0.2%), 2 intracardiac thrombus (0.4 %), and 14 others (3.1%).  Mean TTR was increased from 53.6% to 56.4% when compared before to after the project (p value 0.035 at 95% CI -8.373 to -0.674). There were 239 patients who attended warfarin clinic before and maintained after the project, of these, mean TTR increased from 47.11% to 58.38% (p value 0.021 at 95% CI -14.935 to -7.612). Thrombosis and bleeding complications were reduced from 13.96 per 100 patient-years to 11.29 per 100 patient-years.

Conclusions: The development of holistic care in warfarin clinic by multidisciplinary team improved outcomes of treatment, it significantly increased mean TTR from 53.64% to 56.38% and reduced thrombosis and bleeding complications from 13.96 per 100 patient-years to 11.29 per 100 patient-years.

Author Biography

Rawiwan Thongsongsang, M.D., Division of Medicine, Nakhonpathom Hospital

MSc Internal Medicine

References

1. Heeringa J, van der Kuip DA, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006;27(8):949-53.

2. Krahn AD, Manfreda J, Tate RB, et al. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med 1995;98:476–84.

3. Karthikeyan G, Eikelboom JW. The CHADS2 score for stroke risk stratification in atrial fibrillation. Thromb Haemost 2010;104:45-8.

4. Olesen JB, Lip GY, Hansen ML, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ 2011;342:d124.

5. Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012;33:2719-47.

6. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 2014;130:2071-104.

7. Rosendaal FR, Cannegieter SC, van der Meer FJ, et al. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993;69:236-9.

8. Di Minno A, Frigerio B, Spadarella G, et al. Old and new oral anticoagulants: Food, herbal medicines and drug interactions. Blood Rev 2017;31(4):193-203.

9. Van der Meer FJ, Rosendaal FR, Vanderbrouke JP, et al. Bleeding complications in oral anticoagulant therapy an analysis of risk factors. Arch Inten Med 1993;153: 1557-62.

10. Patareli G, Leali N, Coccher S, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Lancet 1996;348: 423-8.

11. Caldeira D, Cruz I, Morgado G, et al. Is the time in therapeutic range using the ratio of tests equivalent to the Rosendaal method?. Blood Coagul Fibrinolysis 2015;26:972-6.

12. Asarcıklı LD, Şen T, İpek EG, et al. Time in Therapeutic Range (TTR) Value of Patients who use Warfarin and Factors which Influence TTR. J Am Coll Cardiol 2013;62(18 Suppl 2):C127-8.

13. พัทยา หวังสุข, สุนิดา แสงย้อย. การพัฒนาเครือข่ายการดูแลผู้ป่วยใช้ยาวาร์ฟาริน ในโรงพยาบาลส่งเสริมสุขภาพตําบล อําเภอปทุมราชวงศา จังหวัดอํานาจเจริญ. วารสารวิชาการสาธารณสุข 2557:23;45-51.

Downloads

Published

2019-09-25

How to Cite

1.
Thongsongsang R. The Outcomes and Complications in Patients Taking Warfarin under the Development of Holistic Care and Multidisciplinary-Team Approach in Nakhonpathom Hospital. Reg 4-5 Med J [internet]. 2019 Sep. 25 [cited 2026 Feb. 21];38(3):196-208. available from: https://he02.tci-thaijo.org/index.php/reg45/article/view/217966

Issue

Section

Original Article